A Phase 1 interventional study of MT-1186 in Healthy Adult Subjects, sponsored by Shionogi. Completed at 1 site in Japan. Open to participants aged 20 Years to 45 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-07-15.
Sponsored by Shionogi · Phase 1, Interventional, and Basic science
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
To evaluate the effect of food on the pharmacokinetics of oral edaravone in healthy adult subjects. In this study, we determined 5 different dietary conditions including 4 different meal contents and fasting condition.
Shionogi is the lead sponsor of 105 studies on the registry; 10 are open to participants now.
Of its 39 completed or terminated interventional studies of FDA-regulated products, 21 (54%) have results posted.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Subjects who meet all of the following criteria and who have the capability of giving will be included in the study.
Exclusion Criteria:
Subjects who met any of the following exclusion criteria between screening and product administration were excluded from the study:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis C tests
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECG (electrocardiogram)
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
QT and QTc
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A single oral dose of MT-1186 with fasted condition in period 1, meal 1 condition in period 2, meal 2 condition in period 3, meal 3 condition in period 4, and meal 4 condition in period 5.
Drug: MT-1186
A single oral dose of MT-1186 with meal 1 condition in period 1, meal 2 condition in period 2, meal 3 condition in period 3, fasted condition in period 4, and meal 4 condition in period 5.
Drug: MT-1186
A single oral dose of MT-1186 with meal 2 condition in period 1, meal 3 condition in period 2, fasted condition in period 3, meal 1 condition in period 4, and meal 4 condition in period 5.
Drug: MT-1186
A single oral dose of MT-1186 with meal 3 condition in period 1, fasted condition in period 2, meal 1 condition in period 3, meal 2 in period 4, and meal 4 condition in period 5.
Drug: MT-1186
A crossover study in which Japanese healthy subjects receive a single dose of MT-1186 under several dosing condition on Day 1, 3, 5, 7 and 24 according to their treatment sequence.
Also known as: Edaravone
Area Under the Concentration Versus Time Curve From Zero up to Infinity (AUC0-inf) of Edaravone
Time frame: Before administration, 0.083, 0.25, 0.5, 0.75, 1, 1.5, 2, 4, 6, 8, 10, 12, 24, 36 and 48 hours after administration
Maximum Plasma Concentration (Cmax) of Edaravone
Time frame: Before administration, 0.083, 0.25, 0.5, 0.75, 1, 1.5, 2, 4, 6, 8, 10, 12, 24, 36 and 48 hours after administration
AUC0-inf of Sulfate Conjugate and Glucuronide Conjugate
Time frame: Before administration, 0.083, 0.25, 0.5, 0.75, 1, 1.5, 2, 4, 6, 8, 10, 12, 24, 36 and 48 hours after administration
Cmax of Sulfate Conjugate and Glucuronide Conjugate
Time frame: Before administration, 0.083, 0.25, 0.5, 0.75, 1, 1.5, 2, 4, 6, 8, 10, 12, 24, 36 and 48 hours after administration
Time to Reach Maximum Plasma Concentration (Tmax) of Unchanged Edaravone, Sulfate Conjugate and Glucuronide Conjugate
Time frame: Before administration, 0.083, 0.25, 0.5, 0.75, 1, 1.5, 2, 4, 6, 8, 10, 12, 24, 36 and 48 hours after administration
Terminal Elimination Half-life (t1/2) of Unchanged Edaravone, Sulfate Conjugate and Glucuronide Conjugate
Time frame: Before administration, 0.083, 0.25, 0.5, 0.75, 1, 1.5, 2, 4, 6, 8, 10, 12, 24, 36 and 48 hours after administration
Apparent Terminal Elimination Rate Constant (Kel) of Unchanged Edaravone, Sulfate Conjugate and Glucuronide Conjugate
Time frame: Before administration, 0.083, 0.25, 0.5, 0.75, 1, 1.5, 2, 4, 6, 8, 10, 12, 24, 36 and 48 hours after administration
Mean Residence Time (MRT) of Unchanged Edaravone
Time frame: Before administration, 0.083, 0.25, 0.5, 0.75, 1, 1.5, 2, 4, 6, 8, 10, 12, 24, 36 and 48 hours after administration
Apparent Total Clearance (CL/F) of Unchanged Edaravone
Time frame: Before administration, 0.083, 0.25, 0.5, 0.75, 1, 1.5, 2, 4, 6, 8, 10, 12, 24, 36 and 48 hours after administration
Apparent Distribution Volume at Elimination Phase (Vz/F) of Unchanged Edaravone
Time frame: Before administration, 0.083, 0.25, 0.5, 0.75, 1, 1.5, 2, 4, 6, 8, 10, 12, 24, 36 and 48 hours after administration
Apparent Distribution Volume at Steady State (Vss/F) of Unchanged Edaravone
Time frame: Before administration, 0.083, 0.25, 0.5, 0.75, 1, 1.5, 2, 4, 6, 8, 10, 12, 24, 36 and 48 hours after administration
Cumulative Urinary Excretion Amount (Ae 0-24h) of Unchanged Edaravone, Sulfate Conjugate and Glucuronide Conjugate
Time frame: Day 1 to 9, Day 24 to 26
Urinary Excretion Ratio (Ae% 0-24h) of Unchanged Edaravone, Sulfate Conjugate and Glucuronide Conjugate
Time frame: Day 1 to 9, Day 24 to 26
Renal Clearance (CLr) of Unchanged Edaravone
Time frame: Day 1 to 9, Day 24 to 26
Number of Participants With Adverse Events and Adverse Drug Reactions
Time frame: Day 1 to Day 31
| Milestone | Group A | Group B | Group C | Group D |
|---|---|---|---|---|
| Started | 4 | 4 | 4 | 4 |
| Completed | 4 | 4 | 4 | 4 |
| Not completed | 0 | 0 | 0 | 0 |
| Milestone | Group A | Group B | Group C | Group D |
|---|---|---|---|---|
| Started | 4 | 4 | 4 | 4 |
| Completed | 4 | 4 | 4 | 4 |
| Not completed | 0 | 0 | 0 | 0 |
| Milestone | Group A | Group B | Group C | Group D |
|---|---|---|---|---|
| Started | 4 | 4 | 4 | 4 |
| Completed | 4 | 4 | 4 | 4 |
| Not completed | 0 | 0 | 0 | 0 |
| Milestone | Group A | Group B | Group C | Group D |
|---|---|---|---|---|
| Started | 4 | 4 | 4 | 4 |
| Completed | 4 | 4 | 4 | 4 |
| Not completed | 0 | 0 | 0 | 0 |
| Milestone | Group A | Group B | Group C | Group D |
|---|---|---|---|---|
| Started | 4 | 4 | 4 | 4 |
| Completed | 4 | 4 | 4 | 4 |
| Not completed | 0 | 0 | 0 | 0 |
| ng·h/mL | Edaravone Single Dose Under Fasting Condition | Edaravone Single Dose 8 Hours After a High-fat Meal | Edaravone Single Dose 4 Hours After a Low-fat Meal | Edaravone Single Dose 2 Hours After a Light Meal | Edaravone Single Dose 2 Hours After a Low-fat Meal |
|---|---|---|---|---|---|
| Area Under the Concentration Versus Time Curve From Zero up to Infinity (AUC0-inf) of Edaravone | 2165 ± 673 | 2209 ± 658 | 2073 ± 641 | 1955 ± 523 | 1717 ± 463 |
| ng/mL | Edaravone Single Dose Under Fasting Condition | Edaravone Single Dose 8 Hours After a High-fat Meal | Edaravone Single Dose 4 Hours After a Low-fat Meal | Edaravone Single Dose 2 Hours After a Light Meal | Edaravone Single Dose 2 Hours After a Low-fat Meal |
|---|---|---|---|---|---|
| Maximum Plasma Concentration (Cmax) of Edaravone | 2318 ± 1229 | 2525 ± 1337 | 2020 ± 1114 | 1898 ± 865.9 | 1276 ± 805.6 |
| ng·h/mL | Edaravone Single Dose Under Fasting Condition | Edaravone Single Dose 8 Hours After a High-fat Meal | Edaravone Single Dose 4 Hours After a Low-fat Meal | Edaravone Single Dose 2 Hours After a Light Meal | Edaravone Single Dose 2 Hours After a Low-fat Meal |
|---|---|---|---|---|---|
| Sulfate conjugate | 24519 ± 7243 | 25724 ± 7729 | 24671 ± 6077 | 25903 ± 8657 | 26293 ± 10355 |
| Glucuronide conjugate | 4054 ± 791 | 3895 ± 796 | 4109 ± 891 | 3914 ± 841 | 4325 ± 1054 |
| ng/mL | Edaravone Single Dose Under Fasting Condition | Edaravone Single Dose 8 Hours After a High-fat Meal | Edaravone Single Dose 4 Hours After a Low-fat Meal | Edaravone Single Dose 2 Hours After a Light Meal | Edaravone Single Dose 2 Hours After a Low-fat Meal |
|---|---|---|---|---|---|
| Sulfate conjugate | 8456 ± 2041 | 9024 ± 2430 | 8629 ± 1960 | 8665 ± 2362 | 7986 ± 2288 |
| Glucuronide conjugate | 2283 ± 496.2 | 2209 ± 645.9 | 2283 ± 486.7 | 2141 ± 548.1 | 2031 ± 608.9 |
| h | Edaravone Single Dose Under Fasting Condition | Edaravone Single Dose 8 Hours After a High-fat Meal | Edaravone Single Dose 4 Hours After a Low-fat Meal | Edaravone Single Dose 2 Hours After a Light Meal | Edaravone Single Dose 2 Hours After a Low-fat Meal |
|---|---|---|---|---|---|
| Unchanged edaravone | 0.38 (0.25 to 0.50) | 0.25 (0.08 to 0.75) | 0.50 (0.25 to 0.75) | 0.38 (0.25 to 1.00) | 0.50 (0.25 to 1.50) |
| Sulfate conjugate | 0.75 (0.50 to 0.75) | 0.63 (0.50 to 1.00) | 0.75 (0.50 to 1.00) | 0.75 (0.50 to 1.50) | 1.00 (0.75 to 1.50) |
| Glucuronide conjugate | 0.50 (0.50 to 1.00) | 0.50 (0.50 to 1.00) | 0.75 (0.50 to 1.00) | 0.50 (0.50 to 1.50) | 0.75 (0.50 to 1.00) |
| h | Edaravone Single Dose Under Fasting Condition | Edaravone Single Dose 8 Hours After a High-fat Meal | Edaravone Single Dose 4 Hours After a Low-fat Meal | Edaravone Single Dose 2 Hours After a Light Meal | Edaravone Single Dose 2 Hours After a Low-fat Meal |
|---|---|---|---|---|---|
| Unchanged edaravone | 8.17 ± 2.29 | 7.38 ± 1.97 | 9.05 ± 5.07 | 7.31 ± 4.3 | 11.25 ± 8.35 |
| Sulfate conjugate | 6.32 ± 1.85 | 7.16 ± 2.52 | 5.85 ± 1.18 | 6.25 ± 1.69 | 4.91 ± 1.02 |
| Glucuronide conjugate | 4.12 ± 0.34 | 4.07 ± 0.41 | 4.12 ± 0.46 | 4.03 ± 0.7 | 3.67 ± 0.34 |
| 1/h | Edaravone Single Dose Under Fasting Condition | Edaravone Single Dose 8 Hours After a High-fat Meal | Edaravone Single Dose 4 Hours After a Low-fat Meal | Edaravone Single Dose 2 Hours After a Light Meal | Edaravone Single Dose 2 Hours After a Low-fat Meal |
|---|---|---|---|---|---|
| Unchanged edaravone | 0.0931 ± 0.0343 | 0.0999 ± 0.0248 | 0.1010 ± 0.0645 | 0.1108 ± 0.0330 | 0.0864 ± 0.0435 |
| Sulfate conjugate | 0.1164 ± 0.0249 | 0.1062 ± 0.0300 | 0.1221 ± 0.0195 | 0.1172 ± 0.0246 | 0.1463 ± 0.0266 |
| Glucuronide conjugate | 0.1690 ± 0.0125 | 0.1720 ± 0.0162 | 0.1699 ± 0.0173 | 0.1762 ± 0.0254 | 0.1905 ± 0.0176 |
| h | Edaravone Single Dose Under Fasting Condition | Edaravone Single Dose 8 Hours After a High-fat Meal | Edaravone Single Dose 4 Hours After a Low-fat Meal | Edaravone Single Dose 2 Hours After a Light Meal | Edaravone Single Dose 2 Hours After a Low-fat Meal |
|---|---|---|---|---|---|
| Mean Residence Time (MRT) of Unchanged Edaravone | 2.35 ± 0.52 | 2.19 ± 0.49 | 2.34 ± 0.44 | 2.32 ± 0.54 | 3.55 ± 0.87 |
| L/h | Edaravone Single Dose Under Fasting Condition | Edaravone Single Dose 8 Hours After a High-fat Meal | Edaravone Single Dose 4 Hours After a Low-fat Meal | Edaravone Single Dose 2 Hours After a Light Meal | Edaravone Single Dose 2 Hours After a Low-fat Meal |
|---|---|---|---|---|---|
| Apparent Total Clearance (CL/F) of Unchanged Edaravone | 53.0 ± 16.3 | 51.4 ± 14.4 | 55.1 ± 16.9 | 57.9 ± 17.6 | 65.4 ± 17.3 |
| L | Edaravone Single Dose Under Fasting Condition | Edaravone Single Dose 8 Hours After a High-fat Meal | Edaravone Single Dose 4 Hours After a Low-fat Meal | Edaravone Single Dose 2 Hours After a Light Meal | Edaravone Single Dose 2 Hours After a Low-fat Meal |
|---|---|---|---|---|---|
| Apparent Distribution Volume at Elimination Phase (Vz/F) of Unchanged Edaravone | 608 ± 247 | 530 ± 156 | 646 ± 239 | 585 ± 305 | 993 ± 666 |
| L | Edaravone Single Dose Under Fasting Condition | Edaravone Single Dose 8 Hours After a High-fat Meal | Edaravone Single Dose 4 Hours After a Low-fat Meal | Edaravone Single Dose 2 Hours After a Light Meal | Edaravone Single Dose 2 Hours After a Low-fat Meal |
|---|---|---|---|---|---|
| Apparent Distribution Volume at Steady State (Vss/F) of Unchanged Edaravone | 126.4 ± 57.2 | 114.2 ± 46.7 | 128.6 ± 41.6 | 136.1 ± 59.0 | 231.4 ± 84.0 |
| mg | Edaravone Single Dose Under Fasting Condition | Edaravone Single Dose 8 Hours After a High-fat Meal | Edaravone Single Dose 4 Hours After a Low-fat Meal | Edaravone Single Dose 2 Hours After a Light Meal | Edaravone Single Dose 2 Hours After a Low-fat Meal |
|---|---|---|---|---|---|
| Unchanged edaravone | 0.819 ± 0.349 | 1.609 ± 2.630 | 0.977 ± 0.406 | 0.988 ± 0.965 | 1.302 ± 2.086 |
| Sulfate conjugate | 13.87 ± 12.62 | 13.10 ± 12.61 | 13.13 ± 13.99 | 13.14 ± 10.96 | 8.89 ± 9.50 |
| Glucuronide conjugate | 144.6 ± 19.9 | 146.8 ± 20.5 | 144.0 ± 18.4 | 153.2 ± 22.6 | 160.2 ± 44.8 |
| % of dose | Edaravone Single Dose Under Fasting Condition | Edaravone Single Dose 8 Hours After a High-fat Meal | Edaravone Single Dose 4 Hours After a Low-fat Meal | Edaravone Single Dose 2 Hours After a Light Meal | Edaravone Single Dose 2 Hours After a Low-fat Meal |
|---|---|---|---|---|---|
| Unchanged edaravone | 0.780 ± 0.349 | 1.533 ± 2.505 | 0.931 ± 0.386 | 0.941 ± 0.919 | 1.240 ± 1.986 |
| Sulfate conjugate | 9.08 ± 8.27 | 8.58 ± 8.26 | 8.60 ± 9.17 | 8.61 ± 7.18 | 5.82 ± 6.22 |
| Glucuronide conjugate | 68.7 ± 9.5 | 69.7 ± 9.7 | 68.4 ± 8.8 | 72.8 ± 10.7 | 76.1 ± 21.3 |
| L/h | Edaravone Single Dose Under Fasting Condition | Edaravone Single Dose 8 Hours After a High-fat Meal | Edaravone Single Dose 4 Hours After a Low-fat Meal | Edaravone Single Dose 2 Hours After a Light Meal | Edaravone Single Dose 2 Hours After a Low-fat Meal |
|---|---|---|---|---|---|
| Renal Clearance (CLr) of Unchanged Edaravone | 0.419 ± 0.271 | 0.818 ± 1.413 | 0.535 ± 0.333 | 0.545 ± 0.535 | 0.871 ± 1.582 |
| Participants | Edaravone Single Dose Under Fasting Condition | Edaravone Single Dose 8 Hours After a High-fat Meal | Edaravone Single Dose 4 Hours After a Low-fat Meal | Edaravone Single Dose 2 Hours After a Light Meal | Edaravone Single Dose 2 Hours After a Low-fat Meal |
|---|---|---|---|---|---|
| Number of Participants with Adverse events | 0 | 0 | 1 | 0 | 0 |
| Number of Participants with adverse drug reactions | 0 | 0 | 0 | 0 | 0 |
Collected over Day 1 to Day 31. Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Edaravone Single Dose Under Fasting Condition | 0/16 (0%) | 0/16 (0%) | 0/16 (0%) |
| Edaravone Single Dose 8 Hours After a High-fat Meal | 0/16 (0%) | 0/16 (0%) | 0/16 (0%) |
| Edaravone Single Dose 4 Hours After a Low-fat Meal | 0/16 (0%) | 0/16 (0%) | 1/16 (6.3%) |
| Edaravone Single Dose 2 Hours After a Light Meal | 0/16 (0%) | 0/16 (0%) | 0/16 (0%) |
| Edaravone Single Dose 2 Hours After a Low-fat Meal | 0/16 (0%) | 0/16 (0%) | 0/16 (0%) |
| Event | Edaravone Single Dose Under Fasting Condition | Edaravone Single Dose 8 Hours After a High-fat Meal | Edaravone Single Dose 4 Hours After a Low-fat Meal | Edaravone Single Dose 2 Hours After a Light Meal | Edaravone Single Dose 2 Hours After a Low-fat Meal |
|---|---|---|---|---|---|
| UrticariaSkin and subcutaneous tissue disorders | 0/16 | 0/16 | 1/16 | 0/16 | 0/16 |
| Age, Categorical(Participants) | Group A | Group B | Group C | Group D | Total |
|---|---|---|---|---|---|
| <=18 years | 0 | 0 | 0 | 0 | 0 |
| Between 18 and 65 years | 4 | 4 | 4 | 4 | 16 |
| >=65 years | 0 | 0 | 0 | 0 | 0 |
| Sex: Female, Male(Participants) | Group A | Group B | Group C | Group D | Total |
|---|---|---|---|---|---|
| Female | 1 | 1 | 1 | 1 | 4 |
| Male | 3 | 3 | 3 | 3 | 12 |
| Race (NIH/OMB)(Participants) | Group A | Group B | Group C | Group D | Total |
|---|---|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 | 0 | 0 |
| Asian | 4 | 4 | 4 | 4 | 16 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 | 0 | 0 |
| Black or African American | 0 | 0 | 0 | 0 | 0 |
| White | 0 | 0 | 0 | 0 | 0 |
| More than one race | 0 | 0 | 0 | 0 | 0 |
| Unknown or Not Reported | 0 | 0 | 0 | 0 | 0 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: No
Ran from Jun 2019 to primary completion in Jul 2019, 1 month.
Results were first posted in Jan 2024, 4 years 5 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jun 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Edaravone